Ocugen Inc. (OCGN)
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion.
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical
Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet needs in ophthalmology. I assign OCGN a Buy rating, citing strong clinical data, upcoming pivotal trial catalysts, and sufficient cash runway, despite high commercial and execution risk. Key upcoming catalysts include Phase 3 data for OCU400 and OCU410ST (Stargardt) in 2027 and a Phase 3 trial for OCU410 now FDA-cleared.
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar Musunuri said during a Canaccord discussion.
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
Ocugen Q2 Earnings Call Highlights
Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago.
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
Ocugen NASDAQ: OCGN outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis pigmentosa and Stargardt disease next year and a third BLA for geographic atrophy in 2028.
Ocugen (OCGN) Upgraded to Buy: Here's Why
Ocugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
Ocugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.
Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript
